Leptin as a surrogate immune-metabolic marker to predict impact of anti-cachectic therapy: results of a prospective randomized trial in multiple solid tumors
Leptin is a reliable predictive marker for multitargeted anti-cachectic treatment outcomes. Thus, it can be an ideal candidate for monitoring and predicting the effects of anti-cachectic treatment and a surrogate marker of the immune-metabolic actions of the selected drugs.
Authors
- Andrea Pretta (ORCID: https://orcid.org/0000-0002-0262-9270)
- Giulia Gramignano
- M. Scartozzi
- Gérard A. Pinna (ORCID: https://orcid.org/0000-0002-0815-873X)
- Luciana Tanca
- Eleonora Lai (ORCID: https://orcid.org/0000-0002-0275-8187)
- Daniele Farci
- Clelia Madeddu (ORCID: https://orcid.org/0000-0001-8940-6987)
- M.C. Cherchi
- C. Floris
- Antonio Maccio'
Institutions
- University of Cagliari (IT)
- Azienda Ospedaliero-Universitaria Cagliari (IT)
- Azienda Ospedaliera G. Brotzu (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103738
- Citations
- 1
- Primary Topic
- Adipokines, Inflammation, and Metabolic Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Associazione Sarda per la Ricerca in Oncologia Ginecologica ONLUS